Yondelis Ya Genera Royalties Desde Canada ... Vía Valeo Pharma . Valeo_Pharma Reports its Third Quarter 2020 Results and Highlights .

In June 2020, the Company received a Notice of Compliance from Health Canada authorizing the transfer of the commercial rights of Yondelis® to Valeo. Yondelis® (trabectedin) is a novel marine-derived antitumor agent manufactured by PharmaMar S.A., based in Madrid, Spain .

In August 2020, the Company commenced commercializing Yondelis® in Canada .